| Market Cap | 113.70B | P/E | 30.30 | EPS this Y | 4.80% | Ern Qtrly Grth | 31.70% |
| Income | 3.93B | Forward P/E | 15.68 | EPS next Y | 7.30% | 50D Avg Chg | -1.00% |
| Sales | 32.58B | PEG | 3.00 | EPS past 5Y | 5.72% | 200D Avg Chg | 2.00% |
| Dividend | 3.00% | Price/Book | 2.21 | EPS next 5Y | 5.51% | 52W High Chg | -11.00% |
| Recommedations | 2.50 | Quick Ratio | 1.35 | Shares Outstanding | 1.28B | 52W Low Chg | 13.00% |
| Insider Own | 0.26% | ROA | 4.42% | Shares Float | 1.28B | Beta | 0.85 |
| Inst Own | 85.96% | ROE | 7.95% | Shares Shorted/Prior | 12.70M/14.84M | Price | 85.46 |
| Gross Margin | 65.53% | Profit Margin | 12.06% | Avg. Volume | 5,171,690 | Target Price | 94.75 |
| Oper. Margin | 17.51% | Earnings Date | Nov 19 | Volume | 5,408,180 | Change | -2.53% |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
| Evercore ISI Group | Outperform | Oct 1, 24 |
| Citigroup | Neutral | Oct 1, 24 |
| Truist Securities | Hold | Aug 23, 24 |
| Barclays | Overweight | Aug 22, 24 |
| Oppenheimer | Perform | Aug 21, 24 |
| Piper Sandler | Neutral | Aug 21, 24 |
| RBC Capital | Sector Perform | Aug 21, 24 |
| Wells Fargo | Overweight | Aug 21, 24 |
| Baird | Neutral | Aug 21, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Wall Brett A. | EVP & Pres Neuroscie.. EVP & Pres Neuroscience | Dec 19 | Sell | 82.17 | 4,997 | 410,603 | 28,910 | 12/20/23 |
| Smith Gregory L | EVP Global Ops & Sup.. EVP Global Ops & Supply Chain | Aug 23 | Sell | 83.84 | 10,000 | 838,400 | 46,723 | 08/25/23 |
| Wall Brett A. | EVP & Pres Neuroscie.. EVP & Pres Neuroscience | Aug 14 | Sell | 83.38 | 1,000 | 83,380 | 33,573 | 08/16/23 |
| Marinaro Michael | EVP & President, Sur.. EVP & President, Surgical OU | Aug 03 | Sell | 84.11 | 1,352 | 113,717 | 28,930 | 08/07/23 |
| Salmon Sean | EVP & President Card.. EVP & President Cardiovascular | Dec 13 | Option | 55.32 | 16,631 | 920,027 | 52,719 | 12/16/22 |
| Salmon Sean | EVP & President Card.. EVP & President Cardiovascular | Dec 13 | Sell | 80.5 | 16,631 | 1,338,796 | 36,088 | 12/16/22 |
| TEN HOEDT ROB | EVP and Pres. Global.. EVP and Pres. Global Regions | Oct 14 | Option | 41.6 | 2,404 | 100,006 | 45,887 | 10/17/22 |
| TEN HOEDT ROB | EVP and Pres. Global.. EVP and Pres. Global Regions | Oct 14 | Sell | 81.54 | 2,404 | 196,022 | 43,483 | 10/17/22 |
| PARKHILL KAREN L | EVP & Chief Financia.. EVP & Chief Financial Officer | Mar 18 | Sell | 110.00 | 682 | 75,020 | 34,946 | 03/21/22 |
| Surface Carol A | SVP, Chief HR Office.. SVP, Chief HR Officer | Mar 11 | Sell | 105.30 | 6,000 | 631,800 | 28,502 | 03/14/22 |
| Salmon Sean | EVP & Pres Diabetes/.. EVP & Pres Diabetes/Cardiovasc | Aug 26 | Option | 38.61 | 28,419 | 1,097,258 | 40,619 | 08/26/21 |
| Salmon Sean | EVP & Pres Diabetes/.. EVP & Pres Diabetes/Cardiovasc | Aug 26 | Sell | 134.09 | 28,419 | 3,810,704 | 33,329 | 08/26/21 |
| Martha Geoffrey | CEO CEO | Aug 26 | Sell | 132.67 | 11,581 | 1,536,451 | 95,836 | 08/26/21 |
| Martha Geoffrey | CEO CEO | Aug 26 | Option | 59.04 | 11,581 | 683,742 | 105,936 | 08/26/21 |
| Wall Brett A. | EVP & Pres Neuroscie.. EVP & Pres Neuroscience | Jun 22 | Option | 74.84 | 1,168 | 87,413 | 22,655 | 06/22/21 |
| Wall Brett A. | EVP & Pres Neuroscie.. EVP & Pres Neuroscience | Jun 22 | Sell | 123.5 | 115 | 14,202 | 21,602 | 06/22/21 |
| Liddicoat John R | EVP & President of A.. EVP & President of Americas | Jun 01 | Option | 83.03 | 34,656 | 2,877,488 | 77,207 | 06/01/21 |
| WHITE ROBERT JOHN | EVP & Pres. Medical.. EVP & Pres. Medical Surgical | Dec 21 | Sell | 115.46 | 10,930 | 1,261,978 | 44,922 | 12/21/20 |
| Lerman Bradley E | SVP General Counsel.. SVP General Counsel & Corp Sec | Nov 10 | Option | 62.76 | 20,715 | 1,300,073 | 74,863 | 11/10/20 |
| Lerman Bradley E | SVP General Counsel.. SVP General Counsel & Corp Sec | Nov 10 | Sell | 113.13 | 20,715 | 2,343,488 | 54,148 | 11/10/20 |
| ISHRAK OMAR | Executive Chairman Executive Chairman | Oct 14 | Sell | 108.4 | 763 | 82,709 | 561,032 | 10/14/20 |
| Lerman Bradley E | SVP General Counsel.. SVP General Counsel & Corp Sec | Oct 09 | Option | 62.76 | 20,714 | 1,300,011 | 55,122 | 10/09/20 |
| Lerman Bradley E | SVP General Counsel.. SVP General Counsel & Corp Sec | Oct 09 | Sell | 110 | 20,714 | 2,278,540 | 54,325 | 10/09/20 |